The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus

References

• Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010;95:34-42
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Norton L, DeFronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011;32:515-31
   PubMed Web of Science ®Google Scholar
• Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010;70:377-85
   PubMed Web of Science ®Google Scholar
• Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009;75:1272-7
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012;14:5-14
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-8
   PubMed Web of Science ®Google Scholar
• Wilding JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 2014;63:1228-37
   PubMed Web of Science ®Google Scholar
• Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001;280:F10-8
   PubMed Web of Science ®Google Scholar
• Chen J, Williams S, Ho S, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 2010;1:57-92
   PubMedGoogle Scholar
• Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011;91:733-94
   PubMed Web of Science ®Google Scholar
• Zhou L, Cryan EV, D’Andrea MR, et al. Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J Cell Biochem 2003;90:339-46
   PubMed Web of Science ®Google Scholar
• Liang Y, Arakawa K, Ueta K, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 2012;7:e30555
   PubMed Web of Science ®Google Scholar
• Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 2013;36:2154-61
   PubMed Web of Science ®Google Scholar
• Devineni D, Curtin CR, Polidori D, et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 2013;53:601-10
   PubMed Web of Science ®Google Scholar
• Kissner T, Doyle N, Samadfam R, et al. Bone as a target tissue in the toxicological assessment of anti-diabetes drug class of SGLT1 inhibitors. Presented at: 49th Annual Meeting of the Society of Toxicology; March 7–11, 2010; Salt Lake City, Utah. Abstract 117.
   Google Scholar
• Tirmenstein M, Dorr TE, Janovitz EB, et al. Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor. Int J Toxicol 2013;32:336-50
   PubMed Web of Science ®Google Scholar
• Ways K, Johnson MD, Mamidi RNVS, et al. Successful integration of non-clinical and clinical findings in interpreting the clinical relevance of rodent neoplasia with a new chemical entity. Toxicol Pathol J 2015;43:48-56
   PubMed Web of Science ®Google Scholar
• Mamidi RNVS, Proctor J, De Jonghe S, et al. Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin. Chem Biol Interact 2014;221:109-18
   PubMed Web of Science ®Google Scholar
• De Jonghe S, Proctor J, Vinken P, et al. Carcinogenicity in rats of the antidiabetic SGLT2 inhibitor canagliflozin. Chem Biol Interact 2014;224:1-12
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA Briefing Document. NDA 202293 Dapagliflozin tablets, 5 and 10 mg. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. 19 July 2011. Available at: http://www.fda.gov/downloads/AdvisoryCommittee/UCM262994.pdf [Last accessed 11 January 2016]
   Google Scholar
• European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). European public assessment report (EPAR) for Jardiance (empagliflozin). EMEA/H/C/002677/0000. 20 March 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002677/WC500168594.pdf [Last accessed 11 January 2016]
   Google Scholar
• Barone S, Fussell SL, Singh AK, et al. Slc2a5 (Glut5) is essential for the absorption of fructose in the intestine and generation of fructose-induced hypertension. J Biol Chem 2009;284:5056-66
   PubMed Web of Science ®Google Scholar
• Sha S, Devineni D, Ghosh A, et al. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS One 2014;9:e105638
   PubMed Web of Science ®Google Scholar
• Bode B, Stenlöf K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995) 2013;41:72-84
   PubMedGoogle Scholar
• Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013;15:463-73
   PubMed Web of Science ®Google Scholar
• Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014;16:1016-27
   PubMed Web of Science ®Google Scholar
• Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab 2013;15:1136-45
   PubMed Web of Science ®Google Scholar
• Iijima H, Kifuji T, Maruyama N, Inagaki N. Pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with type 2 diabetes mellitus. Adv Ther 2015;32:768-82
   PubMed Web of Science ®Google Scholar
• Weir MR, Kline I, Xie J, et al. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin 2014;30:1759-68
   PubMed Web of Science ®Google Scholar
• List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-7
   PubMed Web of Science ®Google Scholar
• Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014;85:962-71
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 2013;36:4015-21
   PubMed Web of Science ®Google Scholar
• Haring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014;37:1650-9
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2015;17:936-48
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28
   PubMed Web of Science ®Google Scholar
• Bilezikian JP, Watts NB, Usiskin K, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. J Clin Endocrinol Metab 2016;101:44-51
   PubMed Web of Science ®Google Scholar
• Bays HE, Weinstein R, Law G, Canovatchel W. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring) 2014;22:1042-9
   PubMed Web of Science ®Google Scholar
• Ljunggren O, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2012;14:990-9
   PubMed Web of Science ®Google Scholar
• Hyldstrup L, Andersen T, McNair P, et al. Bone metabolism in obesity: changes related to severe overweight and dietary weight reduction. Acta Endocrinol (Copenh) 1993;129:393-8
   PubMedGoogle Scholar
• Bleicher K, Cumming RG, Naganathan V, et al. The role of fat and lean mass in bone loss in older men: findings from the CHAMP study. Bone 2011;49:1299-305
   PubMed Web of Science ®Google Scholar
• Hinton PS, Rector RS, Linden MA, et al. Weight-loss-associated changes in bone mineral density and bone turnover after partial weight regain with or without aerobic exercise in obese women. Eur J Clin Nutr 2012;66:606-12
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Johnson KC, Kahn SE, et al. Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: results from the Look AHEAD randomized trial. J Bone Miner Res 2012;27:619-27
   PubMed Web of Science ®Google Scholar
• Bode B, Stenlöf K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes. Diabetes Obes Metab 2015;17:294-303
   PubMed Web of Science ®Google Scholar
• Villareal DT, Fontana L, Weiss EP, et al. Bone mineral density response to caloric restriction-induced weight loss or exercise-induced weight loss: a randomized controlled trial. Arch Intern Med 2006;166:2502-10
   PubMedGoogle Scholar
• Fleischer J, Stein EM, Bessler M, et al. The decline in hip bone density after gastric bypass surgery is associated with extent of weight loss. J Clin Endocrinol Metab 2008;93:3735-40
   PubMed Web of Science ®Google Scholar
• Skov AR, Haulrik N, Toubro S, et al. Effect of protein intake on bone mineralization during weight loss: a 6-month trial. Obes Res 2002;10:432-8
   PubMedGoogle Scholar
• Jensen LB, Quaade F, Sorensen OH. Bone loss accompanying voluntary weight loss in obese humans. J Bone Miner Res 1994;9:459-63
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-50
   PubMed Web of Science ®Google Scholar
• Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2016;101:157-66
   PubMed Web of Science ®Google Scholar
• INVOKANA^® (canagliflozin) tablets, for oral use [package insert]. Titusville, NJ, USA: Janssen Pharmaceuticals, 2015
   Google Scholar
• US Food and Drug Administration. FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm [Last accessed 11 January 2016]
   Google Scholar
• Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 2005;20:452-77
   PubMedGoogle Scholar
• Harada N, Inagaki N. Role of sodium-glucose transporters in glucose uptake of the intestine and kidney. J Diabetes Investig 2012;3:352-3
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-24
   PubMed Web of Science ®Google Scholar
• Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013;1:208-19
   PubMed Web of Science ®Google Scholar
• Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82
   PubMed Web of Science ®Google Scholar
• Forxiga (dapagliflozin) 5 mg and 10 mg film-coated tablets [summary of product characteristics]. Middlesex, United Kingdom: Bristol-Myers Squibb/AstraZeneca EEIG, 2014
   Google Scholar
• INVOKANA (canagliflozin) tablets, for oral use [summary of product characteristics]. Beerse, Belgium: Janssen-Cilag International NV, 2015
   Google Scholar
• Jardiance (empagliflozin) 10 mg film-coated tablets [summary of product characteristics]. Ingelheim, Germany: Boehringer Ingelheim GmbH, 2014
   Google Scholar
• Quarles LD. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol 2012;8:276-86
   PubMed Web of Science ®Google Scholar
• Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015;100:2849-52
   PubMed Web of Science ®Google Scholar
• Rejnmark L, Vestergaard P, Brot C, Mosekilde L. Increased fracture risk in normocalcemic postmenopausal women with high parathyroid hormone levels: a 16-year follow-up study. Calcif Tissue Int 2011;88:238-45
   PubMed Web of Science ®Google Scholar
• Hernandez JL, Olmos JM, Pariente E, et al. Influence of vitamin D status on vertebral fractures, bone mineral density, and bone turnover markers in normocalcemic postmenopausal women with high parathyroid hormone levels. J Clin Endocrinol Metab 2013;98:1711-7
   PubMed Web of Science ®Google Scholar
• Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol 2015;3:8-10
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Quarles LD. Fibroblast growth factor-23: what we know, what we don’t know, and what we need to know. Nephrol Dial Transplant 2013;28:2228-36
   PubMed Web of Science ®Google Scholar
• Larsson T, Marsell R, Schipani E, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004;145:3087-94
   PubMed Web of Science ®Google Scholar
• Arnlov J, Carlsson AC, Sundstrom J, et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 2013;83:160-6
   PubMed Web of Science ®Google Scholar
• Mirza MA, Larsson A, Melhus H, et al. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009;207:546-51
   PubMed Web of Science ®Google Scholar
• Wolf M, Molnar MZ, Amaral AP, et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011;22:956-66
   PubMed Web of Science ®Google Scholar
• Parker BD, Schurgers LJ, Brandenburg VM, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010;152:640-8
   PubMed Web of Science ®Google Scholar
• Yamout HM, Perkovic V, Davies M, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol 2014;40:64-74
   PubMed Web of Science ®Google Scholar
• Berlie HD, Garwood CL. Diabetes medications related to an increased risk of falls and fall-related morbidity in the elderly. Ann Pharmacother 2010;44:712-7
   PubMed Web of Science ®Google Scholar
• Maurer MS, Burcham J, Cheng H. Diabetes mellitus is associated with an increased risk of falls in elderly residents of a long-term care facility. J Gerontol A Biol Sci Med Sci 2005;60:1157-62
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Hillier TA, Sellmeyer DE, et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002;25:1749-54
   PubMed Web of Science ®Google Scholar